A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2011; you can also visit the original URL.
The file type is
The increasing use of methotrexate for multiple indications in reproductive age women will likely lead to more frequent incidence of fetal exposure. Methotrexate is sometimes used for medical termination of first trimester pregnancy in combination with misoprostol. Teratogenesis in women exposed to low-dose methotrexate used for treatment of rheumatic conditions has been reported, but it has also been suggested that there is no teratogenic risk associated with low-dose exposure. Because medicaldoi:10.3844/ajptsp.2007.146.147 fatcat:oigtiuwg4jbdvipyxuta5sihhe